Learned lots in this “How I Treat Steroid-Refractory GVHD” from Paul Martin! 3 🔑points: -“Truth be told, we don't know how to treat SRGVHD.” -Only 10 open clinical trials! 😬 -Need risk-adapted trials w/ clinical & biomarker risk stratification 🥳 ashpublications.org/blood/article/…

#DrugRepurposing is ♨️right now, with good reason. It’s the fastest way to develop new 💊 in times of urgent need. This is the #Tweetstory behind our #ClinicalTrial using #hCG in severe #GVHD just published in Blood Advances. Still an urgent need. ashpublications.org/bloodadvances/…

Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians rdcu.be/b3wr8

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease | NEJM www-nejm-org.eresources.mssm.edu/doi/full/10.10…

Latest advances in HCT and cellular therapy a post TCT summary part II ... youtu.be/xQwUxumIZmQ An impressive and comprehensive summary by Dr Bipin Savani for IACH

"The dignity of a physician requires that he should look healthy, and as plump as nature intended him to be...and anointed with sweet-smelling unguents that are not in any way suspicious." - the sage wisdom of Hippocrates

Cellular ‘backpacks’ keep immune cells in attack mode against tumors statnews.com/2020/05/05/cel… via STAT

Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD | Nature Reviews Clinical Oncology rdcu.be/b34qH #gvhdsm #bmtsm

Brain cell transplant for Parkinson’s 😲 statnews.com/2020/05/12/med… via STAT

Congratulations to Dr. James Ferrara for winning the Mount Sinai Faculty Mentorship Award 🥳! He cares so much about his trainees and has helped me grow tremendously. Nobody more deserving! The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai #GVHDsm #BMTsm

Plasma #ACE2 and risk of death or #cardiometabolic diseases: a case-cohort study The Lancet Sukrit Narula (1st author) et al #PUREstudy sciencedirect.com/science/articl… Marie Pigeyre

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

WOW! StanfordMedRes residents FEARLESSLY going up against a derm differential presented masterfully by the one and only PGY3 Ani Tarimala, MD! This was the story of a middle aged women with diffuse blistering rash, found to have TB induced hypersensitivity!

CONGRESS #EBMT23 | James Ferrara Mount Sinai Health System describes the use of a serum biomarker & clinical response 2 weeks after treatment as a composite endpoint. N = 1,138. This combo correctly reclassifies 1/2 of clinical NRs as late responders who have excellent OS. #GvHD #bmtsm

CONGRESS #EBMT23 | John Levine Mount Sinai Health System discusses risk assessment in acute #GvHD in this educational session with a focus on biomarkers. He states that the best #GvHD biomarkers quantify damage to the GI tract (e.g. ST2+Reg3a) the organ most resistant to treatment #bmtsm

What are the guidelines to manage the newly defined CAR T-cell therapy-related HLH-like syndrome? Check out our summary here 👉 loom.ly/VjvZgnY. #lymsm

CONGRESS|#EHA2023 Matthew Frank Stanford Medicine discusses the safety and efficacy of CD22 CART therapy in pts with LBCL who have relapsed after CD19 CART therapy. The ORR and CR rates were 68% and 53%, respectively #lymphoma #lymsm #medicalcongress

New #JITC article: Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma bit.ly/45Rv2Rc Hrishi Srinagesh

Combining CAR-T cells targeting CD19 & CD22 with a recombinant, polymer-conjugated IL15 receptor agonist (NKTR-255) was safe and feasible. ow.ly/Lqn450TNNN3 #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia #transplantation